Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...
Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...
Analysts at HC Wainwright issued their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback